



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Oversight Committee Meeting Minutes

November 19, 2015

1. Meeting Called to Order

A quorum being present, Presiding Officer Geren called the Oversight Committee to order at 10:30 a.m.

2. Roll Call /Excused Absences

Board Members Present:

Angelos Angelou (absent)

Donald (Dee) Margo

Pete Geren

Ned Holmes

Will Montgomery

Cynthia Mulrow, M.D.

Amy Mitchell

Bill Rice, M.D.

Craig Rosenfeld, M.D.

MOTION:

Presiding Officer Geren called for a motion to excuse the absence of Mr. Angelou.

Motion made by Dr. Rice and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

3. Adoption of Minutes from the November 19, 2015, Oversight Committee Meeting (TAB 1)

MOTION:

Presiding Officer Geren called for a motion to approve the minutes of the November 19, 2015 Oversight Committee meeting.

Motion made by Mr. Margo and seconded by Mr. Holmes

MOTION CARRIED UNANIMOUSLY

4. Public Comment

Presiding Officer Geren recognized Mr. Danny Ingram, Executive Vice President of the American Cancer Society (ACS) High Plains Division.

Mr. Ingram thanked the agency for its work and noted that ACS' mission aligns with CPRIT's mission. He presented an overview of ACS' Hope Lodge Initiative. Lack of transportation and/or lodging may contribute cancer patients not consistently receiving or completing recommended treatment. Hope Lodge fills that need. One Hope Lodge is located in Texas providing these free services to cancer patients, but ACS plans to open two more in Houston and Dallas.

Mr. Ingram responded to an Oversight Committee member question explaining that the program is need-blind versus need-based, and completely free to anyone. A donor campaign funds the costs. They begin operations with enough funding for at least three years of operations to ensure consistency of services. Donor funding campaigns will be continuous. He also explained that Hope Lodges are different from Ronald McDonald houses in that their services are for everyone, not just for families with sick children. They collaborate with Hospice and navigate patients to those services as needed.

There were no other requests for public comment.

5. Chief Executive Officer Report (TAB 2)

Mr. Wayne Roberts, Chief Executive Officer, reported on agency activities such as the recent *CPRIT Innovations in Cancer Prevention and Research Conference* held on November 9 and 10, 2015 and the status of selected CPRIT staff personnel recruitments.

Mr. Roberts also discussed grant-funding issues, including the process to ensure that Prevention Program grants do not exceed the 10% statutory maximum, FY 2016 funding available for grant awards, and targets for each program for planning purposes.

An Oversight Committee member asked whether Prevention funding had ever gone over the 10% statutory cap. Mr. Roberts said that the funding had exceeded the limit. Dr. Garcia reported that the Prevention Program is trying to address the issue by moving their grant cycle so that it is in the last funding cycle presented to the Oversight Committee in August. By that time, staff has a much clearer picture of the final budget. Ms. Doyle added the issue of possibly going over the statutory cap of 10% for Prevention arises when prospective recruits decline awards after the fiscal year closes. Staff has proposed amending CPRIT administrative rule 703.12 to provide transparency in our process for how we are establishing the budget for Prevention. It will call for the Chief Executive Officer to present the operating budget at the first meeting following the fiscal year and to update the budget at each meeting.

An Oversight Committee member stated that the agency would not want to find that they had awarded more than the amount the Legislature authorized. Mr. Roberts stated that staff should be able to avoid that situation by having updates at each meeting as appropriate.

An Oversight Committee member asked whether a set percentage of funding should be allotted to Academic Research and to Product Development Research because the large number of available Academic Research awards could outweigh the fewer available Product Development awards. Dr. Kripke pointed out that a drawback of setting specific amounts is

that one program may not have enough meritorious awards for all of the available funding, which leaves money unspent or approval of less worthy awards. If the money is unspent, it lowers the total amount of funds awarded used to calculate Prevention's 10% cap. CPRIT cannot carry forward the unspent funds in all cases into the next fiscal year.

Presiding Officer Geren requested that the Oversight Committee plan to consider this issue and develop a policy.

One Oversight Committee member asked if the agency could do anything to avoid the funding issues created when potential recruits decline grants after the fiscal year. Dr. Kripke said establishing a deadline to accept awards is an option. However, changing the timing of the awards is difficult because the awards follow the recruitment cycle of the universities. Moving the second Prevention Program cycle so that the awards come to the August Oversight Committee for approval helps alleviate the problem.

Presiding Officer Geren emphasized that CPRIT is going to do everything possible to abide by the 10% statutory cap on Prevention funding and legislative staff is aware of our commitment.

There were no further questions for Mr. Roberts.

6. Personnel – Chief Scientific Officer (Agenda Item 20 taken out of order)

Presiding Officer Geren announced that the Chief Executive Officer had requested an opportunity to update the Oversight Committee on the recruitment activities for the Chief Scientific Officer position. He stated that pursuant to Texas Government Code § 551.074, the meeting would go into closed session to discuss personnel issues related to the Chief Scientific Officer. He invited Wayne Roberts, Dr. Kripke, and Ms. Doyle to join the committee in the closed session.

Presiding Officer Geren announced the time the Oversight Committee went into closed session at 12:43 p.m.

Presiding Officer Geren reconvened the open meeting at 1:26 p.m. The Oversight Committee did not take action on this issue.

7. Chief Scientific Officer Report (TAB 3)

Presiding Officer Geren noted that the grant award recommendations were in the meeting materials handout titled "Proposed Grant Awards."

Dr. Margaret Kripke, Chief Scientific Officer recounted the Academic Research Program activities set out in her report in the Meeting Packet.

Dr. Kripke and the Oversight Committee discussed computational biology applications. She noted that the Scientific Review Council recommended only one computational biology application from cycle 16.1. Staff plans to meet with potential grant applicants and provide some guidance before the next round of applications. She anticipates that CPRIT will accept more applications in the future. An Oversight Committee member asked why the success rate was so low in computational biology. Dr. Kripke responded that the major reason appears that the biology part was weak even though a collaborator in biology was required. Many times the named collaborator had little input into the actual process. Reviewers also felt that applications were lacking in not having a demonstration project. The University Advisory Committee has provided feedback that many computational biologists are not primary investigators on grants and therefore not versed in grant application process. More training for computational biology applicants could help alleviate these issues.

In response to an Oversight Committee member's question, Dr. Kripke said they would explore the feasibility of adding a computational biology component to the individual investigator requests for application.

After Dr. Kripke presented the data on cancer by site, an Oversight Committee member noted the percent of grants targeting pancreatic cancer seems low in comparison to other targeted cancers.

Dr. Kripke noted that this cycle there were 13 applications for training grants and six of those were renewals. Of those six, the PIC recommended only three for funding. There were seven new applications for training grants. CPRIT allowed institutions to submit more than one application if one of the applications was in the area of prevention or epidemiology, one of the seven submitted was in this area.

In the area of recruitment awards, the PIC was recommending an extraordinarily large dollar amount for approval. The institutions are beginning to recruit senior researchers and those awards are more expensive. This is something that will need to be monitored going forward because they will compete with the academic research and product development grants for available funds. With that in mind, Mr. Roberts asked if the Oversight Committee wanted to prioritize the younger, up and coming researchers over the more senior established researchers. An Oversight Committee member noted that recruitment of established researchers includes funding to support their research and they contribute to economic development. Dr. Kripke said there are reasons to fund both new and established investigators and it will be a policy decision for the Oversight Committee.

An Oversight Committee member requested that Dr. Kripke routinely provide information on how many people investigators bring with their grants. Dr. Kripke stated this would also be an appropriate time to start surveying grantees on what they have accomplished and how successful they have been in terms of generating new funding or creating new jobs.

Presiding Officer Geren requested that Mr. Roberts provide information to the Oversight Committee on how to survey former grantees to determine their continuing contributions to cancer research.

Dr. Kripke presented the following Academic Research award recommendations for the Oversight Committee's consideration:

Academic Research Grant Award Recommendations

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160157	The University of Texas Southwestern Medical Center	Cancer Intervention and Prevention Discoveries Program	RTA-Renewal	\$3,993,250
RP160192	Baylor College of Medicine	Decoding Cellular Heterogeneity of Malignant Glioma	IIRA	\$899,701
RP160451	Baylor College of Medicine	Protein Truncation Mutations in WIP1: Effects on Cancer and Hematopoiesis	IIRA	\$900,000
RP160180	The University of Texas Southwestern Medical Center	Development of Therapeutics Targeting Truncated Adenomatous Polyposis Coli (APC) as a Novel Prevention and Intervention Strategy for Colorectal Cancer	IIRA	\$900,000
RP160237 *	The University of Texas M. D. Anderson Cancer Center	A novel epigenetic reader as therapeutic target in MLL-translocated pediatric leukemias	IIRACC A	\$900,000
RP160283	Baylor College of Medicine	Baylor College of Medicine Comprehensive Cancer Training Program	RTA-Renewal	\$3,986,268
RP160487	The University of Texas Health Science Center at San Antonio	Cytokine signaling in Ewing sarcoma	IIRACC A	\$1,200,000
RP160030	The University of Texas Southwestern Medical Center	A Randomized Controlled Trial (RCT) of Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System	IIRAP	\$1,492,616
RP160384	Baylor College of Medicine	Promoting The Functions of Memory T cells for Adoptive T cell Therapy	IIRA	\$887,676

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160318	The University of Texas Southwestern Medical Center	Role of Long Non-Coding RNAs in Breast Cancer: Identification, Characterization, and Determination of Molecular Functions	IIRA	\$886,652
RP160589	Texas AgriLife Research	Arylhydrocarbon receptor mediated modulation of colorectal cancer by microbiota metabolites	IIRAP	\$890,840
RP160190 **	The University of Texas Southwestern Medical Center	Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE)	IIRACC A	\$900,000
RP160497	The University of Texas M. D. Anderson Cancer Center	Amplified gold nanoparticle-mediated radiosensitization of tumors	IIRA	\$899,309
RP160229	The University of Texas M. D. Anderson Cancer Center	Imaging-based quantitative analysis of vascular perfusion and tissue oxygenation to improve therapy of hepatocellular carcinoma	IIRA	\$885,901
RP160169	The University of Texas Southwestern Medical Center	Molecular Mechanism of NLRP12-mediated Regulation of Colorectal Cancer	IIRA	\$897,707
RP160249 ***	The University of Texas Southwestern Medical Center	DIS3L2 in Childhood Wilms Tumor: Mechanism to Medicines	IIRACC A	\$1,200,000
RP160089	The University of Texas Southwestern Medical Center	Carbamoyl Phosphate Synthase-1: A new metabolic liability in non-small cell lung cancers	IIRA	\$900,000
RP160501	The Methodist Hospital Research Institute	De-Orphanizing TLX: Implications for Glioblastomas	IIRA	\$878,969
RP160622	The University of Texas Southwestern Medical Center	Computational live cell histology	IIRACB	\$392,779

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160097	Baylor College of Medicine	Cancer Prevention Post-Graduate Training Program in Integrative Epidemiology	RTA	\$2,986,890
RP160015	The University of Texas Health Science Center at Houston	Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers	RTA-Renewal	\$4,000,000
RP160340	The University of Texas Southwestern Medical Center	The role of the Lats kinases in sarcomatoid renal cell carcinoma	IIRA	\$899,598
RP160183	The University of Texas M. D. Anderson Cancer Center	Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas	IIRA	\$900,000
RP160232	The University of Texas M. D. Anderson Cancer Center	Understanding Biological and Physical Factors Affecting Response to Proton Therapy to Improve its Clinical Effectiveness	IIRA	\$879,362
RP160022	Baylor College of Medicine	Role of Cohesin in Hematopoiesis and Myeloid Leukemia in Children with Down Syndrome	IIRACC A	\$1,905,638
RP160242	The University of Texas M. D. Anderson Cancer Center	Mechanisms and targeting strategies for SWI/SNF mutations in cancer	IIRA	\$900,000
RP160440	The University of Texas Southwestern Medical Center	Targeting the undruggable: a first- in- class inhibitor of the HIF-2 transcription factor	IIRA	\$899,412
RP160145	The University of Texas M. D. Anderson Cancer Center	Early Detection of Ovarian Cancer with Tumor Associated Proteins and Autoantibodies	IIRAP	\$1,497,595
RP160013	The University of Texas M. D. Anderson Cancer Center	Visualizing T-cell trafficking	IIRA	\$900,000

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160019	The University of Texas M. D. Anderson Cancer Center	An Adaptive Personalized Clinical Trial using a Patient-Derived Xenograft Strategy to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma	IIRA	\$841,606
RP160051	Texas A&M University System Health Science Center	Improving contrast for antibody- based tumor detection using PET	IIRA	\$887,134
RP160023	The University of Texas M. D. Anderson Cancer Center	Investigating the genetic and molecular mechanisms underlying RAS/ERK substrate network	IIRA	\$900,000
RP160211	The University of Texas Southwestern Medical Center	Novel tumorigenic mechanisms of the LKB1 tumor suppressor in endometrial and cervical cancer	IIRA	\$896,653
RP160319	The University of Texas Southwestern Medical Center	Role of PARP-1 in Estrogen Receptor Enhancer Function and Gene Regulation Outcomes in Breast Cancers	IIRA	\$884,315
RP160124	The University of Texas Health Science Center at San Antonio	Chemoprevention of Colon Cancer by Anti-inflammatory Blockade Using Neem	IIRAP	\$899,617
RP160188	The University of Texas M. D. Anderson Cancer Center	Regulation of infiltration and function of tumor-resident CD8 T cells by IL-15	IIRA	\$828,060
RP160255	The University of Texas Southwestern Medical Center	Structural and Functional Analyses of the Spindle Checkpoint	IIRA	\$900,000
RP160307	The University of Texas Southwestern Medical Center	Targeting Metastatic Pathways	IIRA	\$900,000

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160517	The University of Texas M. D. Anderson Cancer Center	Exosomal DNA as a surrogate biomarker for early diagnosis and therapeutic stratification in pancreatic cancer	IIRA	\$891,938
RP160345	Baylor College of Medicine	Engineering T cells to ensure specificity for tumor cells and their environment	IIRA	\$900,000
RP160482	The University of Texas M. D. Anderson Cancer Center	Nanoparticle Targeted STAT3 Immune Expression	IIRA	\$888,429
RP160121	The University of Texas M. D. Anderson Cancer Center	Clinical Safety and Efficacy of Third party, fucosylated, cord blood derived regulatory T cells to prevent graft versus host disease	IIRA	\$900,000
RP160520	The University of Texas Southwestern Medical Center	Effect of Chest Radiation Therapy on Cardiomyocyte Turnover	IIRAP	\$897,570
RP160268	The University of Texas Southwestern Medical Center	DNA damage-induced small non-coding RNAs: mechanism and their role in cancer development	IIRA	\$900,000
RP160512	The University of Texas Health Science Center at San Antonio	Integrin-mediated IL-18 signaling in the prevention and treatment of inflammation-associated colorectal cancer	IIRA	\$859,620
RP160577	Baylor Research Institute	A novel function of Itch in controlling IL-17-induced inflammation in colon cancer	IIRA	\$900,000

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160617	The University of Texas at Dallas	Optimizing therapeutic strategies against lung cancer using Multi- Modality Imaging	IIRA	\$899,999
RP160493	The University of Texas Southwestern Medical Center	Characterization and pharmacological targeting of the oncogenic activity of Jumonji enzymes	IIRA	\$899,997
RP160054	Baylor College of Medicine	The CTC Circulator Phenotype: Insights into Mechanisms of Breast Cancer Dormancy	IIRA	\$884,332
RP160235	The University of Texas Health Science Center at Houston	Regulation of tumor aggressiveness and immune suppression in lung adenocarcinoma	IIRA	\$900,000
RP160150	The University of Texas M. D. Anderson Cancer Center	Radiogenomic Screen to Identify Novel Proliferation-associated Glioblastoma Genomic Therapeutic Targets: Discovery and Mechanistic Validation Study	IIRA	\$897,627
RP160460	Rice University	High resolution imaging for early and better detection of bladder cancer	IIRAP	\$873,765
RP160471	The University of Texas M. D. Anderson Cancer Center	Identifying new epigenetic vulnerabilities in pancreatic	IIRA	\$900,000
RP160462	Baylor College of Medicine	Systematic identification of small molecule inhibitors that manipulate telomerase activities	IIRA	\$898,288

App ID	Organization/ Company	Application Title	Mech.	Award Amount
RP160035	Baylor College of Medicine	The role of Prdm16 and histone H3 lysine 9 methyltransferase complex in MDS	IIRA	\$872,157

- * RP160237 - The peer review panel recommended reducing the budget to \$300,000 per year for 3 years for a total of \$900,000 based on the scope and depth of the work proposed.
- ** RP160190 - The peer review panel recommended not funding Aim 4 (Pilot prospective clinical trial) and reducing the budget to \$300,000 per year for 3 years for a total of \$900,000. The final score was based on revised scope with full deletion of Aim 4.
- *** RP160249 - The peer review panel recommended that given the absence of a clinical trial, the budget should be reduced to \$300,000 per year for 4 years for a total of \$1,200,000.

IIRA = Individual Investigator Research Awards
IIRACB = Individual Investigator Research Awards for Computational Biology
IIRACCA = Individual Investigator Research Awards for Cancer in Children and Adolescents
IIRAP = Individual Investigator Research Awards for Prevention and Early Detection
RTA = Research Training Awards
RTA-R = Research Training Awards - Renewal

Academic Research Recruitment Grant Award Recommendations

App ID	Candidate	Organization/Company	Mech.	Budget Requested
RR160019	Dung-fang Lee	The University of Texas Health Science Center at Houston	RFT	\$2,000,000
RR160020	Wei Yang	The University of Texas at Austin	REI	\$6,000,000
RR160022	Andrew D. Rhim	The University of Texas M. D. Anderson Cancer Center	RRS	\$4,000,000
RR160017	Zhijie Liu	The University of Texas Health Science Center at San Antonio	RFT	\$2,000,000
RR160021	Nidhi Sahni	The University of Texas M. D. Anderson Cancer Center	RFT	\$2,000,000

RFT = Recruitment of First-Time, Tenure-Track Faculty Members
REI = Recruitment of Established Investigators
RRS = Recruitment of Rising Stars

COMPLIANCE CERTIFICATION

Mr. Vince Burgess, Chief Compliance Officer, presented his report on the review process for the grant awards recommended to the Oversight Committee. He certified that recommended awards complied with applicable statutory and administrative requirements for the eight academic research slates, the five prevention slates, and the one product development research slate presented for approval at this meeting.

CONFLICT OF INTEREST NOTIFICATIONS

Presiding Officer Geren stated for the record that no Oversight Committee member reported a conflict of interest with any application considered today. No other conflicts were reported.

Presiding Officer Geren stated that rather than taking separate votes on individual grant mechanisms, the Oversight Committee would first take a vote on the individual investigators awards and training grant awards, and then a vote on recruitment grant awards. He noted for the record that a vote to approve the awards would also be an approval of the changes recommended by the peer review committees for RP160249, RP160237, and RP160190.

MOTION:

Presiding Officer Geren entertained a motion to approve each of the Program Integration Committee's recommendations for Individual Investigator awards and Training Grant awards.

Motion made by Mr. Montgomery and seconded by Mr. Margo.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren entertained a motion to approve each of the Program Integration Committee's recommendations for Recruitment Grant awards.

Motion made by Mr. Montgomery and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren entertained a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff, and to authorize the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Motion made by Mr. Montgomery and seconded by Mr. Margo.

MOTION CARRIED UNANIMOUSLY

8. Chief Prevention and Communications Officer Report (TAB 4)

Presiding Officer Geren recognized Dr. Rebecca Garcia to report on the Prevention program activities from August 2015 through November 2015. Dr. Garcia recounted the information provided in the Agenda Packet. She also reported that she was the keynote speaker at a health fair event, “Dia de la Mujer,” held on October 3, 2015, sponsored by Telemundo Amarillo. The event attracted over 500 women.

Grant Award Recommendations:

Dr. Garcia presented the Program Integration Committee’s recommendation to approve grants for twelve projects totaling \$13,247,742. The grant recommendations are presented in five slates corresponding to the grant mechanisms:

Evidence-Based Cancer Prevention Services

App ID	Project Title	Project Director	Organization	Award Amount
PP160042	Using Best Practices to Promote HPV vaccination in Rural Primary Care Settings	Parra-Medina, Deborah	The University of Texas Health Science Center at San Antonio	\$1,295,493
PP160010	Maximizing opportunities for HPV vaccination in the Golden Triangle	Berenson, Abbey B	The University of Texas Medical Branch at Galveston	\$1,409,909
PP160027	Improving Service Delivery to Cancer Survivors in Primary Care Settings	Foxhall, Lewis E	The University of Texas M. D. Anderson Cancer Center	\$1,374,127

Evidence-Based Cancer Prevention Services Colorectal Cancer Prevention Coalition

App ID	Project Title	Project Director	Organization	Award Amount
PP160023	Optimizing Colorectal Cancer Screening in East Texas	Sauter, Edward	The University of Texas Health Center at Tyler	\$2,299,753

Competitive Continuation/Expansion for Evidence-Based Cancer Prevention Services

App ID	Project Title	Project Director	Organization	Award Amount
PP160049	Expansion of a comprehensive cervical cancer screening program for medically underserved women in Harris County	Anderson, Matthew L	Baylor College of Medicine	\$1,500,000

App ID	Project Title	Project Director	Organization	Award Amount
PP160011	GRACIAS Texas: Genetic Risk Assessment for Cancer in All South Texas	Tomlinson, Gail	The University of Texas Health Science Center at San Antonio	\$1,500,000
PP160047	A community based program to increase breast and cervical cancer screening and HPV vaccination to reduce the impact of breast and cervical cancer among Latinas	Savas, Lara	The University of Texas Health Science Center at Houston	\$1,387,005
PP160036	Establishing a Comprehensive Cancer Prevention and Support Program within Asian American Communities in Houston and Austin Areas of Texas	Sun, Helen	Light and Salt Association	\$1,101,986

Cancer Prevention Promotion and Navigation to Clinical Services

App ID	Project Title	Project Director	Organization	Award Amount
PP160032	Family Health History-based Colorectal Cancer Prevention and Navigation to Clinical Services among Uninsured Chinese Americans in Texas	Chen, Lei-Shih	Texas A&M University	\$399,993
PP160056	REACH Rural Education and Awareness for Community Health	Hoelscher, Bill	Coastal Bend Wellness Foundation	\$379,698

Dissemination of CPRIT-Funded Cancer Control Interventions

App ID	Project Title	Project Director	Organization	Award Amount
PP160048	Training CHWs for More Effective Cancer Education and Navigation	Bolin, Jane N	Texas A&M University System Health Science Center	\$300,000
PP160051	Dissemination of an Evidence-Based HPV Vaccination Intervention in Community and Clinical Settings	Fernandez, Maria E	The University of Texas Health Science Center at Houston	\$299,778

COMPLIANCE CERTIFICATION

Presiding Officer Geren noted for the record that Mr. Burgess already certified the review process for all the grant awards recommended to the Oversight Committee during this meeting during the discussion on Agenda Item 7.

CONFLICT OF INTEREST NOTIFICATIONS

Presiding Officer Geren stated for the record that no Oversight Committee member reported a conflict of interest with any application considered today. No other conflicts were reported.

MOTION:

Presiding Officer Geren entertained a motion to approve each of the Program Integration Committee's recommendations for Prevention Grant awards.

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren entertained a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff, and to authorize the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

Contract Extension for PP120029 (TAB 4)

Presiding Officer Geren recognized Ms. Doyle to present the recommendation to approve a contract extension for up to six months for grant award PP120029. The contract extension will allow the Texas Department of State Health Services (DSHS) to use remaining grant funds to pay for an independent audit required by CPRIT's award contract. The approval of the Oversight Committee is necessary because DSHS failed to request a contract extension within the time specified by CPRIT's administrative rules that would have allowed the Chief Executive Officer to approve the extension.

MOTION:

Presiding Officer Geren entertained a motion to approve a contract extension for PP120029 through February 28, 2016.

Motion was made by Mr. Montgomery and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

9. Chief Product Development Officer Report (TAB 5)

Presiding Officer Geren recognized Mr. Michael Lang, Chief Product Development Officer to report on the activities of the Product Development program. He recounted the information in the Agenda Packet.

Grant Award Recommendations

Presiding Officer Geren called upon Mr. Lang to present the Program Integration Committee's recommendation.

Mr. Lang laid out the proposed Product Development award totaling \$20 million to Ruga Corporation (Ruga) for discussion. Ruga is developing a drug for a specific type of leukemia that is in the pre-clinical phase of development. The award allows the company to complete the pre-clinical phase and move the drug forward in the FDA/IND approval process and into a Phase 1 clinical study. The renowned primary investigator's relocation to Texas will help build the cancer research ecosystem.

Mr. Lang reported that the Product Development Review Council (PDRC) was concerned that the license agreement with Stanford University has an unusually high royalty rate. Approval of the award should include a contingency requiring Ruga to renegotiate the license agreement to a standard royalty rate. Another recommended contingency is that Ruga hires an externally facing chief executive officer. The company is new and the primary investigator has been acting as the chief executive officer. The Product Development Review Council (PDRC) also noted a potential issue for clarification related to royalty stacking that might result from their manufacturing contract with FujiFilm Diosynth. The company will also have to report to CPRIT regarding the pre-IND meeting with the FDA.

Mr. Lang reports that the company will be located in Houston. In response to a question from an Oversight Committee member, Mr. Lang stated that the royalty with Stanford is unusually high for this stage in development (15%).

Ms. Doyle pointed out that the company must resolve the contingencies prior to award contract execution. A timeline has been set of May 1, 2016. If for some reason Ruga is unable to renegotiate the royalty rate, the grant money will again become available to fund other grants in this fiscal year.

An Oversight Committee member inquired why a company located in California, where there are other funding opportunities, is coming to Texas. Mr. Lang believes that CPRIT funding and the ecosystem being built in Texas are primary factors in their decision to relocate.

An Oversight Committee member inquired how CPRIT's approval of the renegotiated rate and other contingencies would occur. Ms. Roberts and Ms. Doyle stated that the PDRC recommended that the PDRC review any agreements and make recommendations to CPRIT's Chief Executive Officer.

Product Development Research Grant Award Recommendation

App ID	Company Name	Project	Requested Budget
DP150127	Ruga Corporation	Engineered AXL Decoy Receptor for Treatment of AML & Solid Tumors	\$20,000,000

COMPLIANCE CERTIFICATION

Presiding Officer Geren noted for the record that Mr. Burgess already certified the review process for all the grant awards recommended to the Oversight Committee during this meeting during Item 7.

CONFLICT OF INTEREST NOTIFICATIONS

Presiding Officer Geren stated for the record that no Oversight Committee member reported a conflict of interest with any application considered today. No other conflicts were reported.

MOTION:

Presiding Officer Geren entertained a motion to approve the Program Integration Committee's recommendation for a Product Development Research Grant award to Ruga Corporation, subject to the stated contingencies and the change proposed by Dr. Rosenfeld that Ruga be required to provide the pre-IND meeting minutes to CPRIT for consideration and possible action prior to beginning the second tranche of funding.

Motion was made by Mr. Montgomery and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren entertained a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff, and to authorize the Chief Executive Officer to sign the contract on behalf of CPRIT, with the understanding that the Chief Executive Officer and the Chief Product Development Officer will report to the Product Development Subcommittee for input prior to the contract execution and that the Product Development Subcommittee will make a recommendation to the Chief Executive Officer. Further, if a circumstance arises where the Product Development Subcommittee and the Chief Executive Officer do not agree, the Chief Executive Officer will bring the matter back to the Oversight Committee before proceeding.

Motion was made by Mr. Holmes and seconded by Dr. Rice.

MOTION CARRIED UNANIMOUSLY

MOTION:

Pursuant to the General Appropriations Act, Article IX, Section 4.03(a), Presiding Officer Geren called for a motion to authorize CPRIT to disburse grant funds via advance payments to Ruga Corporation upon execution of the award contract and the successful completion of tranches.

Motion was made by Dr. Rosenfeld and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

10. Scientific Research and Prevention Program Committee Appointments (TAB 6)

Presiding Officer Geren call on Mr. Roberts to present the nominations for the Scientific Research and Prevention Program Committees.

Presiding Officer Geren noted that the Nominations Subcommittee had recommended approval of the proposed nominations.

MOTION:

Presiding Officer Geren called for a motion to approve the Scientific Research and Prevention Program Committee appointments.

Motion was made by Dr. Rosenfeld and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

11. Internal Auditor Report (TAB 7)

Ms. Alyssa Martin of Weaver and Tidwell, CPRIT's internal auditor contractor, presented the following reports:

- Internal Audit Report over Grant Management
Dr. Rice noted that the Audit Subcommittee had requested regular updates on progress of audit findings in order to ensure CPRIT addresses issues timely.
- Internal Audit Follow Up Procedures Report over Prior Year Governance and Information Technology Findings
In response to an Oversight Committee member question, Ms. Martin stated they did not re-perform a full internal audit over Governance or Information Technology. They only performed review of areas with prior findings.
- Internal Audit Follow Up Procedures Report over Prior Year Grantee Monitoring Audit findings
- Internal Audit Report over Expenditures

Presiding Officer Geren reported that the Audit Subcommittee recommended that the Oversight Committee approve these four audit reports.

MOTION:

Presiding Officer Geren called for a motion to approve the Internal Audit Report over Grant Management.

Motion was made by Dr. Rice and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren called for a motion to approve the Internal Audit Follow Up Procedures Report over Prior Year Governance and Information Technology Findings.

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren called for a motion to approve the Internal Audit Report over Prior Year Grantee Monitoring Audit Findings.

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

MOTION:

Presiding Officer Geren called for a motion to approve the Internal Audit Report over Expenditures.

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

FY 2016-FY 2018 Internal Audit Plans

Ms. Martin presented the proposed three-year internal audit plan for FY 2016 through FY 2018. Developing a plan that covers three years allows the agency to plan audits that consistently cover medium to high-risk functions, as defined by the agency's risk assessment. It allows agency staff to implement procedures to address any audit recommendations and the internal auditor to test the effectiveness those new procedures against the original findings.

Ms. Martin explained that with the approval of the plans for three years, the FY 2016 internal audit plan is incorporated into the FY 2015 Internal Audit Annual Report that the Oversight Committee will take action on next.

Presiding Officer Geren pointed out that information security is such a high risk for any organization that it should be reviewed regularly and suggested that an information security audit be included in CPRIT's audit plan every year, not only in FY 2016.

Ms. Martin responded that CPRIT could incorporate the suggestion in the annual risk assessment process that internal audit and agency staff will perform toward the end of FY 2016. It will adjust the audit plans for FY 2017 and future years.

Presiding Officer Geren stated that the Audit Subcommittee recommended that the Oversight Committee approve the FY 2016-FY 2018 Internal Audit Plans.

MOTION:

Presiding Officer Geren called for a motion to approve the FY 2016-FY 2018 Internal Audit Plans

Motion was made by Mr. Montgomery and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

FY 2015 Internal Audit Annual Report

Ms. Martin presented the FY 2015 Internal Audit Annual Report, explaining that it incorporates all of the required elements required by the State Auditor's Office. Once approved by the Oversight Committee, CPRIT will submit the report to the State Auditor's Office and post it on CPRIT's website.

Presiding Officer Geren stated that the Audit Subcommittee recommended that the Oversight Committee approve the FY 2015 Internal Audit Annual Report.

MOTION:

Presiding Officer Geren called for a motion to approve the FY 2015 Internal Audit Annual Report.

Motion was made by Mr. Montgomery and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

12. FY 2016 Program Priorities (TAB 8)

Mr. Roberts presented the FY 2016 Program Priorities for the committee's consideration and approval.

MOTION:

Presiding Officer Geren called for a motion to approve the FY 2016 Program Priorities.

Motion was made by Dr. Rosenfeld and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

13. Proposed Amendment to Oversight Committee Bylaws (TAB 9)

Ms. Doyle explained that the proposed changes to the CPRIT Oversight Committee Bylaws Section 6.3 clarify that the Chief Executive Officer has contract execution authority, subject to approval by the Oversight Committee and specific delegation when necessary. The changes also authorize the Chief Operating Officer to execute contracts, including grant award contracts, in the absence of the Chief Executive Officer with prior notification to the Oversight Committee.

Presiding Officer Geren noted that the Board Governance Subcommittee had reviewed the changes and recommended approval.

MOTION:

Presiding Officer Geren entertained a motion to approve the proposed amendment to Section 6.3 of the Oversight Committee bylaws.

Motion was made by Dr. Rosenfeld and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

14. Subcommittee Assignments (TAB 10)

Presiding Officer Geren reports that based on the Oversight Committee discussion regarding realignment of the subcommittee membership, he and the committee vice chair have recommended subcommittee assignments as presented in the meeting materials for this meeting for the committee's consideration.

MOTION:

Presiding Officer Geren entertained a motion to approve the subcommittee assignments as proposed for FY 2016-FY 2017.

Motion was made by Mr. Holmes and seconded by Dr. Rice.

MOTION CARRIED UNANIMOUSLY

15. Proposed Amendments to 25 T.A.C. Chapter 703 and Authorization to Publish in *Texas Register* (TAB 11)

Ms. Kristen Doyle, General Counsel, presented the many proposed rule amendments to Texas Administrative Code. One of the proposed changes provides more clarity for the process of determining the 10% of grant funds available for prevention grants. A proposed rule also outlines a process for the Chief Executive Officer to approve a no cost extension request that the grantee submits after the required timeframe. In response to a question from the Oversight Committee, Ms. Doyle stated that the proposed rules provide an example of the agency formalizing its commitment to transparency.

MOTION:

Presiding Officer Geren entertained a motion to approve the proposed rule changes for publication in the *Texas Register* for public comment.

Motion was made by Ms. Mitchell and seconded by Dr. Mulrow.

MOTION CARRIED UNANIMOUSLY

16. Final Order Approving Amendments to 25 T.A.C. Chapter 703 (TAB 12)

Ms. Doyle presented the final order approving amendments to CPRIT’s administrative rules. The Oversight Committee preliminarily approved the changes in September 2015. One of the rule changes allows the Prevention grantees to use grant funds for up to 5% of indirect costs. The other change implements a new requirement of compliance training for all grantees. CPRIT published the proposed rules in the *Texas Register* for public comment.

MOTION:

Presiding Officer Geren entertained a motion to approve the final order adopting CPRIT’s rule changes and to direct staff to file the order with the Secretary of State.

Motion was made by Dr. Rice and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

17. Advisory Committee on Childhood Cancer – Charter Amendment (TAB 13)

Dr. Kripke presented the proposed amendments to the charter of the Advisory Committee on Childhood Cancer. The primary change is to the membership makeup—the committee wants to have more than one person from the larger institutions across the state.

MOTION:

Presiding Officer Geren entertained a motion to approve the changes as proposed to the Advisory Committee on Childhood Cancer charter.

Motion was made by Dr. Rice and seconded by Ms. Mitchell.

MOTION CARRIED UNANIMOUSLY

18. Chief Operating Officer Report (TAB 14)

Ms. Heidi McConnell, Chief Operating Officer, presented information on the following topics.

CPRIT Financial Overview for FY 2015, Quarter 4

- FY 2015, Quarter 4 Operating Budget
- FY 2015, Quarter 4 Performance Measures
- Debt Issuance History

Activities since September 1, 2015

- Annual Financial Report
- Annual Financial Audit
- FY 2016 Operating Budget

There were no questions for Ms. McConnell.

19. Chief Compliance Officer Report (TAB 15)

Mr. Vince Burgess, Chief Compliance Officer, reported on the activities of the Compliance program.

- Submission Status of Required Grant Recipient Reports
Mr. Roberts noted that last year there were a large number of out-of-compliance reports and the agency needed to thoroughly investigate issues behind the non-compliance. He stated that under the leadership of Ms. McConnell and Mr. Burgess, staff have upheld their commitment to identify the causes and to reduce the number of non-compliant grants.
- FSR Reviews
- Desk Reviews
- On-site Reviews
- Single Audit Tracking
- Training and Technical Assistance

Presiding Officer Geren said that now that CPRIT has experience with collecting the reports and reviewing the captured information, he would ask that staff consider whether the reports actually capture needed information and if collecting that information is overly burdensome to grantees.

There were no questions for Mr. Burgess.

20. Chief Prevention and Communications Officer Report (TAB 16)

Dr. Rebecca Garcia, Chief Prevention and Communications Officer, presented an overview of the agency's communications activities from August 2015 through Nov. 19, 2015. She also commended Jeff Hillary, Communications Specialist; Ramona Magid, Senior Program Manager for Prevention; and Therry Simien, Information Technology Officer, for their work to make the 2015 CPRIT conference a success. More than 820 people attended the conference and 238 provided written evaluations. The feedback was overwhelmingly positive. Dr. Garcia will draft a conference report for the Oversight Committee.

Dr. Garcia also reports that the "Achievements Report" has been redesigned and updated, CPRIT's message platform is being updated, and that staff are beginning to prepare materials and messaging for the legislative session.

21. Subcommittee Business

Presiding Officer Geren noted for the record that there was nothing to discuss under this standing item.

22. Compliance Investigation Pursuant to Health & Safety Code § 102.2631

Presiding Officer Geren noted for the record that there was nothing to discuss under this standing item.

23. Consultation with General Counsel

Presiding Officer Geren noted for the record that there was nothing to discuss under this standing item.

24. Future Meeting Dates and Agenda Items (TAB 17)

Presiding Officer Geren announced that the next Oversight Committee meeting is February 17, 2016, at 9:00 a.m.

25. Adjourn

MOTION:

There being no further business, Presiding Officer Geren entertained a motion to adjourn.

Motion was made by Dr. Rice and seconded by Mr. Holmes.

MOTION CARRIED UNANIMOUSLY

Meeting adjourned at 2:50 p.m.



Signature

2-17-2016

Date



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

November 5, 2015

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 73 grant applications totaling \$112,009,012. The PIC recommendations for 60 academic research grant awards, 1 product development award, and 12 prevention awards are attached.

Dr. Margaret Kripke, CPRIT's Chief Scientific Officer, Mr. Michael Lang, CPRIT's Chief Product Development Officer, and Dr. Becky Garcia, CPRIT's Chief Prevention Officer, have prepared overviews of the academic research, product development, and prevention program slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all of the information considered by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

For the first time the PIC has used the award deferral process set by CPRIT administrative rule § 703.7(d) to defer the decision to recommend awards for two prevention applications until a future FY 2016 meeting. PP160046 and PP160033, totaling \$2,999,657, were recommended by the Prevention Review Council (PRC). The PIC's unanimous decision conserves prevention award funds for the second FY2016 funding cycle. The two deferred applications were ranked the lowest of the prevention grants recommended for funding. After considering proposals submitted in the next cycle, the PRC may recommend funding one or both deferred applications. No Oversight Committee action is necessary at this time.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on Thursday, November 19, 2015. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Kripke, Mr. Lang, and Dr. Garcia are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts
Chief Executive Officer

*Per Sec Nov. 19, 2015
Way M. Mitchell
11/19/15*

Academic Research Award Recommendations –

The PIC unanimously recommends approval of 60 academic research grant proposals totaling \$78,761,270. The recommended grant proposals were submitted in response to eight grant mechanisms: Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Biology; Individual Investigator Research Awards for Prevention and Early Detection; Research Training Awards; Recruitment of First-Time, Tenure-Track Faculty; Recruitment of Rising Stars, and Recruitment of Established Investigators. The PIC followed the recommendations made by the Scientific Review Council (SRC). The SRC provided the prioritized list of recommendations for the Recruitment awards to the presiding officers on October 26, 2015. Dr. Kolodner corrected a score for one grant, RP160268, in a letter dated October 29, 2015, which slightly affected the grant's ranking.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state (the PIC chose this factor for Multi-Investigator Research Awards and High-Impact, High-Risk Research Awards);
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources;
- Expedite innovation and commercialization, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or Technology research capabilities; and
 - This factor only applies to Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Biology; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of First-Time, Tenure-Track Faculty; Recruitment of Rising Stars, and Recruitment of Established Investigators
- address the goals of the Texas Cancer Plan.

Academic Research Grant Award Recommendations

Rank	App ID	Organization/Company	Application Title	Award Amount	Mech.	Overall Score
1	RP160157	The University of Texas Southwestern Medical Center	Cancer Intervention and Prevention Discoveries Program	\$3,993,250	RTA-Renewal	1.2
2	RP160192	Baylor College of Medicine	Decoding Cellular Heterogeneity of Malignant Glioma	\$899,701	IIRA	1.3
3	RP160451	Baylor College of Medicine	Protein Truncation Mutations in WIP1: Effects on Cancer and	\$900,000	IIRA	1.5
4	RP160180	The University of Texas Southwestern Medical Center	Development of Therapeutics Targeting Truncated Adenomatous Polyposis Coli (APC) as a Novel Prevention and Intervention Strategy for Colorectal Cancer	\$900,000	IIRA	1.8
5*	RP160237	The University of Texas M. D. Anderson Cancer Center	A novel epigenetic reader as therapeutic target in MLL-translocated pediatric leukemias	\$900,000	IIRACC A	1.8
6	RP160283	Baylor College of Medicine	Baylor College of Medicine Comprehensive Cancer Training Program	\$3,986,268	RTA-Renewal	1.9
7	RP160487	The University of Texas Health Science Center at San Antonio	Cytokine signaling in Ewing sarcoma	\$1,200,000	IIRACC A	1.9
8	RP160030	The University of Texas Southwestern Medical Center	A Randomized Controlled Trial (RCT) of Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System	\$1,492,616	IIRAP	1.9
9	RP160384	Baylor College of Medicine	Promoting The Functions of Memory T cells for Adoptive T cell Therapy	\$887,676	IIRA	1.9
10	RP1	The University of Texas Southwestern Medical Center	Role of Long Non-Coding RNAs in Breast Cancer: Identification, Characterization, and Determination of Molecular Functions	\$886,652	IIRA	2.0
11	RP160589	Texas AgriLife Research	Arylhydrocarbon receptor mediated modulation of colorectal cancer by microbiota	\$890,840	IIRAP	2.0
12**	RP160190	The University of Texas Southwestern Medical Center	Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE)	\$900,000	IIRACC A	2.0
13	RP160497	The University of Texas M. D. Anderson Cancer Center	Amplified gold nanoparticle-mediated radiosensitization of	\$899,309	IIRA	2.0
14	RP160229	The University of Texas M. D. Anderson Cancer Center	Imaging-based quantitative analysis of vascular perfusion and tissue oxygenation to improve therapy of hepatocellular carcinoma	\$885,901	IIRA	2.0
15	RP160169	The University of Texas Southwestern Medical Center	Molecular Mechanism of NLRP12- mediated Regulation of Colorectal Cancer	\$897,707	IIRA	2.1
16***	RP160249	The University of Texas Southwestern Medical Center	DIS3L2 in Childhood Wilms Tumor: Mechanism to Medicines	\$1,200,000	IIRACC A	2.1

Rank	App ID	Organization/Company	Application Title	Award Amount	Mech.	Overall Score
17	RP160089	The University of Texas Southwestern Medical Center	Carbamoyl Phosphate Synthase-1: A new metabolic liability in non-small cell lung cancers	\$900,000	IIRA	2.1
18	RP160501	The Methodist Hospital Research Institute	De-Orphanizing TLX: Implications for Glioblastomas	\$878,969	IIRA	2.1
19	RP160622	The University of Texas Southwestern Medical Center	Computational live cell histology	\$392,779	IIRACB	2.1
20	RP160097	Baylor College of Medicine	Cancer Prevention Post-Graduate Training Program in Integrative Epidemiology	\$2,986,890	RTA	2.1
21	RP160015	The University of Texas Health Science Center at Houston	Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers	\$4,000,000	RTA-Renewal	2.1
22	RP160340	The University of Texas Southwestern Medical Center	The role of the Lats kinases in sarcomatoid renal cell	\$899,598	IIRA	2.2
23	RP160183	The University of Texas M. D. Anderson Cancer Center	Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches	\$900,000	IIRA	2.2
24	RP160232	The University of Texas M. D. Anderson Cancer Center	Understanding Biological and Physical Factors Affecting Response to Proton Therapy to Improve its Clinical Effectiveness	\$879,362	IIRA	2.2
25	RP160022	Baylor College of Medicine	Role of Cohesin in Hematopoiesis and Myeloid Leukemia in Children with Down Syndrome	\$1,905,638	IIRACC A	2.2
26	RP160242	The University of Texas M. D. Anderson Cancer Center	Mechanisms and targeting strategies for SWI/SNF mutations in cancer	\$900,000	IIRA	2.3
27	RP160440	The University of Texas Southwestern Medical Center	Targeting the undruggable: a first-in-class inhibitor of the HIF-2 transcription factor	\$899,412	IIRA	2.3
28	RP160145	The University of Texas M. D. Anderson Cancer Center	Early Detection of Ovarian Cancer with Tumor Associated Proteins and Autoantibodies	\$1,497,595	IIRAP	2.3
29	RP160013	The University of Texas M. D. Anderson Cancer Center	Visualizing T-cell trafficking	\$900,000	IIRA	2.3
30	RP160019	The University of Texas M. D. Anderson Cancer Center	An Adaptive Personalized Clinical Trial using a Patient-Derived Xenograft Strategy to Overcome Ibrutinib Resistance in Mantle Cell	\$841,606	IIRA	2.3
31	RP160051	Texas A&M University System Health Science Center	Improving contrast for antibody-based tumor detection using PET	\$887,134	IIRA	2.3
32	RP160023	The University of Texas M. D. Anderson Cancer Center	Investigating the genetic and molecular mechanisms underlying RAS/ERK substrate network	\$900,000	IIRA	2.4
33	RP160211	The University of Texas Southwestern Medical Center	Novel tumorigenic mechanisms of the LKB1 tumor suppressor in endometrial and cervical cancer	\$896,653	IIRA	2.4

Rank	App ID	Organization/Company	Application Title	Award Amount	Mech.	Overall Score
34	RP160319	The University of Texas Southwestern Medical Center	Role of PARP-1 in Estrogen Receptor Enhancer Function and Gene Regulation Outcomes in Breast	\$884,315	IIRA	2.4
35	RP160124	The University of Texas Health Science Center at San Antonio	Chemoprevention of Colon Cancer by Anti-inflammatory Blockade Using Neem	\$899,617	IIRAP	2.4
36	RP160188	The University of Texas M. D. Anderson Cancer Center	Regulation of infiltration and function of tumor-resident CD8 T	\$828,060	IIRA	2.4
37	RP160255	The University of Texas Southwestern Medical Center	Structural and Functional Analyses of the Spindle Checkpoint	\$900,000	IIRA	2.5
38	RP160307	The University of Texas Southwestern Medical Center	Targeting Metastatic Pathways	\$900,000	IIRA	2.5
39	RP160517	The University of Texas M. D. Anderson Cancer Center	Exosomal DNA as a surrogate biomarker for early diagnosis and therapeutic stratification in pancreatic cancer	\$891,938	IIRA	2.5
40	RP160345	Baylor College of Medicine	Engineering T cells to ensure specificity for tumor cells and their environment	\$900,000	IIRA	2.5
41	RP160482	The University of Texas M. D. Anderson Cancer Center	Nanoparticle Targeted STAT3 Immune Expression	\$888,429	IIRA	2.6
42	RP160121	The University of Texas M. D. Anderson Cancer Center	Clinical Safety and Efficacy of Third party, fucosylated, cord blood derived regulatory T cells to prevent graft versus host disease	\$900,000	IIRA	2.6
43	RP160520	The University of Texas Southwestern Medical Center	Effect of Chest Radiation Therapy on Cardiomyocyte Turnover	\$897,570	IIRAP	2.6
44	RP160268	The University of Texas Southwestern Medical Center	DNA damage-induced small non-coding RNAs: mechanism and their role in cancer development	\$900,000	IIRA	2.7
45	RP160512	The University of Texas Health Science Center at San Antonio	Integrin-mediated IL-18 signaling in the prevention and treatment of inflammation-associated colorectal cancer	\$859,620	IIRA	2.7
46	RP160577	Baylor Research Institute	A novel function of Itch in controlling IL-17-induced inflammation in colon cancer	\$900,000	IIRA	2.7
47	RP160617	The University of Texas at Dallas	Optimizing therapeutic strategies against lung cancer using Multi-Modality	\$899,999	IIRA	2.7
48	RP160493	The University of Texas Southwestern Medical Center	Characterization and pharmacological targeting of the oncogenic activity of Jumonji	\$899,997	IIRA	2.8
49	RP160054	Baylor College of Medicine	The CTC Circulator Phenotype: Insights into Mechanisms of Breast Cancer Dormancy	\$884,332	IIRA	2.9
50	RP160235	The University of Texas Health Science Center at Houston	Regulation of tumor aggressiveness and immune suppression in lung adenocarcinoma	\$900,000	IIRA	2.9

Rank	App ID	Organization/Company	Application Title	Award Amount	Mech.	Overall Score
51	RP160150	The University of Texas M. D. Anderson Cancer Center	Radiogenomic Screen to Identify Novel Proliferation-associated Glioblastoma Genomic Therapeutic Targets: Discovery and Mechanistic Validation Study	\$897,627	IIRA	3.0
52	RP160460	Rice University	High resolution imaging for early and better detection of bladder	\$873,765	IIRAP	3.0
53	RP160471	The University of Texas M. D. Anderson Cancer Center	Identifying new epigenetic vulnerabilities in pancreatic	\$900,000	IIRA	3.1
54	RP160462	Baylor College of Medicine	Systematic identification of small molecule inhibitors that manipulate telomerase activities	\$898,288	IIRA	3.2
55	RP160035	Baylor College of Medicine	The role of Prdm16 and histone H3 lysine 9 methyltransferase complex in MDS	\$872,157	IIRA	3.2

*RP160237 - The peer review panel recommended reducing the budget to \$300,000 per year for 3 years for a total of \$900,000 based on the scope and depth of the work proposed.

**RP160190 - The peer review panel recommended not funding Aim 4 (Pilot prospective clinical trial) and reducing the budget to \$300,000 per year for 3 years for a total of \$900,000. The final score was based on revised scope with full deletion of Aim 4.

***RP160249 - The peer review panel recommended that given the absence of a clinical trial, the budget should be reduced to \$300,000 per year for 4 years for a total of \$1,200,000.

Academic Research Recruitment Grant Award Recommendations

Rank	App ID	Candidate	Organization/Company	Mech.	Budget Requested	Overall Score
1	RR160019	Dung-fang Lee	The University of Texas Health Science Center at Houston	RFT	\$2,000,000	1.0
2	RR160020	Wei Yang	The University of Texas at Austin	REI	\$6,000,000	1.0
3	RR160022	Andrew D. Rhim	The University of Texas M. D. Anderson Cancer Center	RRS	\$4,000,000	1.8
4	RR160017	Zhijie Liu	The University of Texas Health Science Center at San Antonio	RFT	\$2,000,000	2.5
5	RR160021	Nidhi Sahni	The University of Texas M. D. Anderson Cancer Center	RFT	\$2,000,000	2.5

RFT = Recruitment of First-Time, Tenure-Track Faculty Members

REI = Recruitment of Established Investigators

RRS = Recruitment of Rising Stars

Product Development Research Award Recommendation –

The PIC unanimously recommends approval of one product development grant proposal totaling \$20,000,000. The recommended grant proposal was submitted in response to the New Company Product Development Award Request for Applications. The Product Development Council (PDRC) recommended one application to the PIC. The PDRC provided its recommendation to the presiding officers on October 26, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer ;
- strengthen and enhance fundamental science in cancer research;
- Ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional (the PIC chose this factor for Established Company Awards);
- address federal or other major research sponsors’ priorities in emerging scientific or technology fields in the area of cancer prevention, or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities; and
- address the goals of the Texas Cancer Plan.

**Product Development Research
Grant Award Recommendation**

Rank	Application ID	Company Name	Project	Requested Budget	Overall Score
1	DP150127	Ruga Corporation	Engineered AXL Decoy Receptor for Treatment of AML & Solid Tumors	\$20,000,000	2.2

Prevention Award Recommendations –

The PIC unanimously recommends approval of 12 prevention grant proposals totaling \$13,247,742. The recommended grant proposals were submitted in response to Evidence-Based Cancer Prevention Services-Colorectal Cancer Prevention Coalition, Competitive Continuation/Expansion-Evidence-Based Cancer prevention Services, Cancer Prevention Promotion and Navigation to Clinical Services, Dissemination of CPRIT-Funded Cancer Prevention and Control Interventions; and Evidence-Based Cancer Prevention Services Request for Applications. The PIC followed the recommendations made by the Prevention Review Council (PRC), including deferring two applications to a future PIC meeting. The PRC provided the prioritized list of recommendations for the prevention awards to the presiding officers on October 27, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these prevention proposals met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.

Prevention Grant Award Recommendations

See pages 9-18 for the prevention grant award recommendations.

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160049	CCE-EBP	Expansion of a comprehensive cervical cancer screening program for medically underserved women in Harris County	Anderson, Matthew L	Baylor College of Medicine	\$1,500,000	1.9			1	
PP160047	CCE-EBP	A community based program to increase breast and cervical cancer screening and HPV vaccination to reduce the impact of breast and cervical cancer among Latinas	Savas, Lara S	The University of Texas Health Science Center at Houston	\$1,387,005	2.7	Steps that will be taken to assess actual # of screenings and vaccinations for participants in educational sessions are not explained. It appears that only women completing the surveys will be followed. Evaluation of outcomes for all	Changes not recommended-PRC reviewed peer review comments and determined those comments did NOT impact decision to recommend or impact rank order	2	

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160042	EBP	Using Best Practices to Promote HPV vaccination in Rural Primary Care Settings	Parra-Medina, Deborah	The University of Texas Health Science Center at San Antonio	\$1,295,493	2.8	participants is not provided, only provided for women completing surveys. Budget is unclear about number of screenings that will be paid for; number of financially supported screening isn't clearly stated.	changes not recommended- PRC reviewed peer review comments and determined they did not impact decision to recommend or impact rank order	3	

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160032	PN	Family Health History-based Colorectal Cancer Prevention and Navigation to Clinical Services among Uninsured Chinese	Chen, Lei-Shih	Texas A&M University	\$399,993	3.0	applicability of the proposed approach may be enhanced. Reviewers would like the applicants to clarify why the increase in the budget from the previous grant to this grant. Why has the per person cost increased so much?	changes not recommended-PRC reviewed peer review comments and determined they did not impact decision to recommend or impact rank order	4	

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
		Americans in Texas								
PP160056	PN	REACH Rural Education and Awareness for Community Health	Hoelscher, Bill	Coastal Bend Wellness Foundation	\$379,698	3.0	Should be clarified that \$25 gift card is not being offered to change the behavior of the participants.	changes not recommended-PRC reviewed peer review comments and determined they did not impact decision to recommend or impact rank order	5	
PP160010	EBP	Maximizing opportunities for HPV vaccination in the Golden Triangle	Berenson, Abbey B	The University of Texas Medical Branch at Galveston	\$1,409,909	3.1	Ask applicants why they do not plan to vaccinate young adults on college campuses. In addition, students	changes not recommended-PRC reviewed peer review comments and determined they did not impact	6	

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160048	DI	Training CHWs for More Effective Cancer Education and Navigation	Bolin, Jane N	Texas A&M University System Health Science Center	\$300,000	3.1	could be used to help with recruitment	decision to recommend or impact rank order	7	
PP160023	EBP-CRC	Optimizing Colorectal Cancer Screening in East Texas	Sauter, Edward	The University of Texas Health Center at Tyler	\$2,299,753	3.3	Recommendation was made in previous application that providing FIT isn't evidence-based for people who are at significant risk for CRC; this isn't consistent with ACS guidelines. Ask how they came	changes not recommended-PRC reviewed peer review comments and determined they did not impact decision to recommend or impact rank order	8	

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160036	CCE-EBP	Establishing a Comprehensive Cancer Prevention and Support Program within Asian American Communities in Houston and Austin Areas of Texas	Sun, Helen	Light and Salt Association	\$1,101,986	3.3	Request that the applicant provides a leadership plan that includes input from the three communities being targeted: Vietnamese, Korean, and Filipino	changes not recommended-PRC reviewed peer review comments and determined they did not impact decision to recommend or impact rank order	9	
PP160027	EBP	Improving Service Delivery to Cancer Survivors in	Foxhall, Lewis E	The University of Texas M. D. Anderson	\$1,374,127	3.5	Not clear how project will add to what is already happening in clinic. This is a large, complex project and not clear how	changes not recommended-PRC reviewed peer review comments and determined they did not impact decision to	10	Recommended out of score order above one with higher score due to

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
		Primary Care Settings		Cancer Center			it will be managed on a daily basis. Budget is weak and justification for some of the positions is lacking	recommend or impact rank order		ROI and cancer type
PP160051	DI	Dissemination of an Evidence-Based HPV Vaccination Intervention in Community and Clinical Settings	Fernandez, Maria E	The University of Texas Health Science Center at Houston	\$299,778	3.6	List of current awards doesn't specify PD participation; it should be verified that PD isn't overcommitted. Budget seems somewhat personnel heavy and accounts for a large majority of voerall costs; careful review of personnel and their exact roles and responsibilities and whether or not	changes not recommended-PRC reviewed peer review comments and determined they did not impact decision to recommend or impact rank order	11	Recommended out of score order above one with higher score due to type of program

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160011	CCE-EBP	GRACIAS Texas: Genetic Risk Assessment for Cancer in All South Texas	Tomlinson, Gail E	The University of Texas Health Science Center at San Antonio	\$1,500,000	2.7	any of the services are duplicative may be warranted.		12	Recommended but ranked out of score order due to 1) ROI may be limited; large numbers need to be screened to identify at risk pop.

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
PP160046	EBP	Using social marketing and mobile school-based vaccination clinics to increase HPV vaccination uptake in high-risk geographic areas	Cuccaro, Paula	The University of Texas Health Science Center at Houston	\$1,499,668	2.2			13	Recommended but out of score order due to 1) geography-several HPV grants in Harris county, 2) ROI-costs for education vs services
PP160033	CCE-EBP	Increasing cancer control behaviors among the underserved: A collaboration with Texas 2-1-1 programs	Fernandez, Maria E	The University of Texas Health Science Center at Houston	\$1,499,989	2.4			14	Recommended but out of score order due to 1) geography-several HPV grants in Harris county, 2) cancer type-availability of breast and cervical services 3) ROI-costs for

App ID	Mech.	App. Title	PD	Org.	Requested Funding	Score	Changes recommended from Peer Review	Review of Recommended Changes from Peer Review	Rank Order Score	Explanation of Rank Order
										education vs services
				Initial funding (Rank #1-12)	\$13,247,742					
				(Rank #13+14)	\$2,999,657					
				2nd funding	\$16,247,399					